Malaya Ranjan Patra (M.R.P)

BSE Limited, also known as the Bombay Stock Exchange (BSE, मुंबई रोखे बाजार), is an Indian stock exchange which is located on Dalal Street in Mumbai. Established in 1875 by cotton merchant Premchand Roychand, it is the oldest stock exchange in Asia, and also the tenth oldest in the world. The BSE is one of the worlds largest stock exchanges by market capitalization with a market cap of US$ 3.8 trillion as of June 2023.

The National Stock Exchange of India Limited, India’s largest stock exchange & world’s largest derivatives exchange. Follow us for updates on exchange traded products, insight on capital markets, Indian economy and investor education. Disclaimer - https://bit.ly/3xgvlFQ

BSE Limited, also known as the Bombay Stock Exchange (BSE, मुंबई रोखे बाजार), is an Indian stock exchange which is located on Dalal Street in Mumbai. Established in 1875 by cotton merchant Premchand Roychand, it is the oldest stock exchange in Asia, and also the tenth oldest in the world. The BSE is one of the worlds largest stock exchanges by market capitalization with a market cap of US$ 3.8 trillion as of June 2023.

The National Stock Exchange of India Limited, India’s largest stock exchange & world’s largest derivatives exchange. Follow us for updates on exchange traded products, insight on capital markets, Indian economy and investor education. Disclaimer - https://bit.ly/3xgvlFQ

Aurigene Oncology Limited (formerly, Aurigene Discovery Technologies Limited) is a clinical stage biotech company committed to bringing novel therapeutics for the treatment of cancer. Based in Bengaluru and Kuala Lumpur, Aurigene is focused on developing innovative therapeutics addressing several hallmarks of cancer and has built comprehensive drug discovery and development capabilities, nurtured a growing team of passionate scientists, and collaborated with partners from across the world. Over the past two decades Aurigene has contributed to delivering 18 novel chemical entities which are currently in clinical development. Aurigene has also out-licensed several first-in-class and best-in-class compounds to pharma and biotech companies for global clinical development, while undertaking clinical POC studies for a few programs on its own. For more information, please visit Aurigene’s website at www.aurigene.com.